Roth Capital Reiterates Buy On Regeneron Following Positive Data From Phase 2b Study
In a research note released today, Roth Capital analyst Joseph Pantginis reiterated coverage with a Buy rating on shares of Regeneron Pharmaceuticals (REGN) and a $382 price target, after REGN and partner Sanofi (SNY) reported new positive data from the Phase IIb study of Dupilumab in patients with moderate-to-severe atopic dermatitis. All doses tested achieved the primary endpoint of Eczema Area & Severity Index (EASI) as well as additional efficacy measures.
Pantginis noted, “We are impressed with the successful outcome of this study, showing a substantial improvement with all dupilumab doses tested and validating the approach of targeting the IL-4 and IL-13 signaling pathway. The companies have initiated a Phase III study of dupilumab in AD with a planned enrollment of 800 patients that will address the long term safety and efficacy of multiple dupilumab doses for patients who were part of previous dupilumab studies. We look forward to the long-term and multiple dose data from this Phase III study as these, if positive, will firmly establish the prolonged efficacy profile of dupilumab”.
According to TipRanks.com, which measures analysts and bloggers success rate based on how their calls perform, analyst Joseph Pantginis currently has an average return of -7.6% and a 39% success rate. Pantginis has a 47.4% average profit recommending REGN, and he is ranked #3155 out of 3210 analysts.